Therapy Areas: Autoimmune
Jiangsu Hengrui Medicine and Arcutis sign exclusive option and licence agreement
5 January 2018 -

Chinese biopharmaceutical company Jiangsu Hengrui Medicine Co Ltd (SSE: 600276) and US biotech Arcutis Inc have entered into an exclusive option and licence agreement for the development and commercialisation of topical applications of Hengrui's investigational drug, SHR0302, for the treatment of dermatology disorders, the two companies announced on Friday.

SHR0302 is a highly potent, selective JAK inhibitor. It is currently in Phase 2 clinical trials for rheumatoid arthritis in China.

"Arcutis has been formed around a team of industry veteran leaders with deep expertise and an admirable track record in developing and commercialising dermatology therapeutics," said Lianshan Zhang, president of global R&D at Hengrui.

"There is high unmet need for a topical therapy with new mechanism of action to effectively address immune-mediated dermatology disorders. We are very excited to be a partner of Arcutis."

Login
Username:

Password: